Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
Despite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression. The development of ICI-resistant disease is one of the pressing issue i...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.948297/full |
| _version_ | 1818475484439117824 |
|---|---|
| author | Silvia D’Amico Patrizia Tempora Ombretta Melaiu Ombretta Melaiu Valeria Lucarini Loredana Cifaldi Loredana Cifaldi Franco Locatelli Franco Locatelli Doriana Fruci |
| author_facet | Silvia D’Amico Patrizia Tempora Ombretta Melaiu Ombretta Melaiu Valeria Lucarini Loredana Cifaldi Loredana Cifaldi Franco Locatelli Franco Locatelli Doriana Fruci |
| author_sort | Silvia D’Amico |
| collection | DOAJ |
| description | Despite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression. The development of ICI-resistant disease is one of the pressing issue in clinical oncology, and the identification of new targets and combination therapies is a crucial point to improve response rates and duration. Antigen processing and presentation (APP) pathway is a key element for an efficient response to ICI therapy. Indeed, malignancies that do not express tumor antigens are typically poor infiltrated by T cells and unresponsive to ICIs. Therefore, improving tumor immunogenicity potentially increases the success rate of ICI therapy. In this review, we provide an overview of the key elements of the APP machinery that can be exploited to enhance tumor immunogenicity and increase the efficacy of ICI-based immunotherapy. |
| first_indexed | 2024-12-10T09:13:11Z |
| format | Article |
| id | doaj.art-0e275229791b475ab0839dbad8997419 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-10T09:13:11Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-0e275229791b475ab0839dbad89974192022-12-22T01:54:56ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-07-011310.3389/fimmu.2022.948297948297Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapySilvia D’Amico0Patrizia Tempora1Ombretta Melaiu2Ombretta Melaiu3Valeria Lucarini4Loredana Cifaldi5Loredana Cifaldi6Franco Locatelli7Franco Locatelli8Doriana Fruci9Department of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, ItalyDepartment of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, ItalyDepartment of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, ItalyDepartment of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Rome, ItalyDepartment of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, ItalyDepartment of Clinical Sciences and Translational Medicine, University of Rome “Tor Vergata”, Rome, ItalyAcademic Department of Pediatrics (DPUO), Bambino Gesù Children Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, ItalyDepartment of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, ItalyCatholic University of the Sacred Heart, Rome, ItalyDepartment of Paediatric Haematology/Oncology and of Cell and Gene Therapy, Bambino Gesù Children’s Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, ItalyDespite the significant clinical advances with the use of immune checkpoint inhibitors (ICIs) in a wide range of cancer patients, response rates to the therapy are variable and do not always result in long-term tumor regression. The development of ICI-resistant disease is one of the pressing issue in clinical oncology, and the identification of new targets and combination therapies is a crucial point to improve response rates and duration. Antigen processing and presentation (APP) pathway is a key element for an efficient response to ICI therapy. Indeed, malignancies that do not express tumor antigens are typically poor infiltrated by T cells and unresponsive to ICIs. Therefore, improving tumor immunogenicity potentially increases the success rate of ICI therapy. In this review, we provide an overview of the key elements of the APP machinery that can be exploited to enhance tumor immunogenicity and increase the efficacy of ICI-based immunotherapy.https://www.frontiersin.org/articles/10.3389/fimmu.2022.948297/fullimmunopeptidometumor antigensantigen processingHLA class Iimmune checkpoint inhibitorsTEIPPs |
| spellingShingle | Silvia D’Amico Patrizia Tempora Ombretta Melaiu Ombretta Melaiu Valeria Lucarini Loredana Cifaldi Loredana Cifaldi Franco Locatelli Franco Locatelli Doriana Fruci Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy Frontiers in Immunology immunopeptidome tumor antigens antigen processing HLA class I immune checkpoint inhibitors TEIPPs |
| title | Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy |
| title_full | Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy |
| title_fullStr | Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy |
| title_full_unstemmed | Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy |
| title_short | Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy |
| title_sort | targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy |
| topic | immunopeptidome tumor antigens antigen processing HLA class I immune checkpoint inhibitors TEIPPs |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.948297/full |
| work_keys_str_mv | AT silviadamico targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT patriziatempora targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT ombrettamelaiu targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT ombrettamelaiu targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT valerialucarini targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT loredanacifaldi targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT loredanacifaldi targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT francolocatelli targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT francolocatelli targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy AT dorianafruci targetingtheantigenprocessingandpresentationpathwaytoovercomeresistancetoimmunecheckpointtherapy |